Shares of MBX Biosciences slid 6.4% to $61.50 on July 10, erasing much of the prior session's surge to an all-time high, with no new company-specific news driving the retreat. The selloff looks like classic profit-taking after a breathtaking run — the stock has gained roughly 352% over the past year — leaving investors to ask whether the underlying drug pipeline can support a company now worth over $3 billion with no approved products and no revenue.
The Data That Lit the Fuse Has Already Been Priced In. On June 12, MBX reported one-year results for its once-weekly hormone-replacement injection for chronic hypoparathyroidism, showing a 57% responder rate at one year, comparable to the 63% seen at 12 weeks . The drug was well tolerated with no treatment-related serious side effects . Investors initially cheered those numbers, but on the day of the announcement the stock actually fell 19% before recovering sharply in subsequent weeks. Today's pullback suggests the rally simply overshot available news.
$440 Million in Cash Buys Time, Not Certainty. MBX reports roughly $440 million in cash as of March 31, 2026, enough to fund operations into 2029 . That means no immediate dilution risk from a stock sale. But the company's Phase 3 trial — the pivotal, large-scale test the FDA requires before approval — is only set to begin in Q3 2026 , with results likely years away. Every quarter without revenue burns cash.
The Competitive Field Is Getting Crowded. MBX isn't the only company chasing this market. Ascendis Pharma's Yorvipath became the first FDA-approved treatment for hypoparathyroidism in adults last year , and AstraZeneca's eneboparatide, acquired for $800 million, met its primary Phase 3 endpoint in March 2025 . With only an estimated 70,000 to 90,000 patients affected in the U.S. , the market may not easily support three entrants.
Wall Street Is Bullish but Not Unanimous. Analysts hold a consensus Buy rating with an average price target around $69, with the highest at $91 . However, Goldman Sachs initiated coverage with a Sell and an $18 target, arguing MBX's platform validity beyond its lead drug remains unproven . That $73 spread between bull and bear cases captures the binary risk embedded in clinical-stage biotech: if Phase 3 succeeds, the stock could double; if it stumbles, the floor is far below.